EA201500941A1 - Способы и композиции для модуляции гамма-глутамилового цикла - Google Patents

Способы и композиции для модуляции гамма-глутамилового цикла

Info

Publication number
EA201500941A1
EA201500941A1 EA201500941A EA201500941A EA201500941A1 EA 201500941 A1 EA201500941 A1 EA 201500941A1 EA 201500941 A EA201500941 A EA 201500941A EA 201500941 A EA201500941 A EA 201500941A EA 201500941 A1 EA201500941 A1 EA 201500941A1
Authority
EA
Eurasian Patent Office
Prior art keywords
gamma
methods
compositions
glutamil
modulation
Prior art date
Application number
EA201500941A
Other languages
English (en)
Other versions
EA030611B1 (ru
Inventor
Дейвид Рубин
Эйал Рубин
Original Assignee
Кэнсер Рисерч Текнолоджи, Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кэнсер Рисерч Текнолоджи, Ллк filed Critical Кэнсер Рисерч Текнолоджи, Ллк
Publication of EA201500941A1 publication Critical patent/EA201500941A1/ru
Publication of EA030611B1 publication Critical patent/EA030611B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

В описании предлагаются фармацевтические композиции, включающие ингибиторы гамма-глутамилового цикла (GGCI) и их некоторые фармацевтически приемлемые соли, и способы их применения.
EA201500941A 2013-03-15 2014-03-15 Способы и композиции для модуляции гамма-глутамилового цикла EA030611B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361801709P 2013-03-15 2013-03-15
PCT/US2014/030053 WO2014145314A2 (en) 2013-03-15 2014-03-15 Methods and compositions for gamma-glutamyl cycle modulation

Publications (2)

Publication Number Publication Date
EA201500941A1 true EA201500941A1 (ru) 2016-07-29
EA030611B1 EA030611B1 (ru) 2018-08-31

Family

ID=51529989

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201500941A EA030611B1 (ru) 2013-03-15 2014-03-15 Способы и композиции для модуляции гамма-глутамилового цикла

Country Status (12)

Country Link
US (4) US9630936B2 (ru)
EP (1) EP2968346B1 (ru)
JP (2) JP6458000B2 (ru)
KR (2) KR20210144942A (ru)
CN (1) CN105246483A (ru)
AU (2) AU2014233168B2 (ru)
CA (2) CA2909510C (ru)
DK (1) DK2968346T3 (ru)
EA (1) EA030611B1 (ru)
FI (1) FI2968346T3 (ru)
IL (2) IL283717B (ru)
WO (1) WO2014145314A2 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2909510C (en) 2013-03-15 2024-04-02 Cancer Research Technology, Llc Methods and compositions for gamma-glutamyl cycle modulation
JP6570512B2 (ja) * 2013-03-22 2019-09-04 ユニバーシティ・オブ・ハワイＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｈａｗａｉｉ 新規なＳｔａｔ３阻害剤
WO2016109002A2 (en) 2014-10-16 2016-07-07 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
CN107382903B (zh) * 2017-05-22 2021-02-26 重庆南松凯博生物制药有限公司 一种抗癌药物中间体的制备方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4011233A (en) * 1973-06-28 1977-03-08 Givaudan Corporation 2-methyl-2-(4-methyl-3-pentene-1-yl) thiazolidine
JPS56133216A (en) * 1980-03-24 1981-10-19 Senjiyu Seiyaku Kk Antitumor agent
JPS57128625A (en) * 1981-01-30 1982-08-10 Rikagaku Kenkyusho Carcinostatic
JPS62501769A (ja) * 1984-12-18 1987-07-16 デイビツト　ラビン 細胞毒性アルデヒドとベニシラミンとの反応性成物を含有する抗腫瘍組成物及びその使用方法
HU200177B (en) * 1985-06-18 1990-04-28 Biogal Gyogyszergyar Process for producing thiazolidinecarboxylic acids and pharmaceutical compositions comprising such compounds
JP2717257B2 (ja) * 1988-03-19 1998-02-18 参天製薬株式会社 光学活性化合物の製造法
US4970221A (en) * 1989-07-28 1990-11-13 E. R. Squibb & Sons, Inc. 3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
NL9001955A (nl) * 1990-09-05 1992-04-01 Cedona Pharm Bv Nieuwe thiazolidinederivaten.
JPH04169858A (ja) 1990-11-02 1992-06-17 Toyota Motor Corp 力学量センサ
US7425635B2 (en) * 1997-08-07 2008-09-16 University Of Utah Research Foundation Prodrugs and conjugates of thiol- and selenol-containing compounds and methods of use thereof
US6723711B2 (en) * 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
NZ535139A (en) 2002-03-22 2007-07-27 Eisai Co Ltd Hemiasterlin derivatives and uses thereof in the treatment of cancer
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
BRPI0415390A (pt) * 2003-10-14 2006-12-12 Pharmacia Corp compostos de pirazinona substituìda para o tratamento da inflamação
DE10348023A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
US20060014740A1 (en) * 2003-11-18 2006-01-19 Miller Duane D Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof
MXPA06005528A (es) * 2003-11-18 2007-01-30 Univ Tennessee Res Foundation Tiazolidinona-amidas, amidas de acido tiazolidina-carboxilico, metodos de elaboracion, y uso de las mismas.
KR100590530B1 (ko) 2003-12-10 2006-06-15 삼성전자주식회사 수직자기기록매체
US20080176923A1 (en) * 2003-12-18 2008-07-24 Salama Zoser B Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors
JP2007522247A (ja) * 2004-02-11 2007-08-09 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション 細胞増殖の阻害を示すアナログ、それを作製する方法およびその使用
KR20060014740A (ko) 2004-08-12 2006-02-16 조정래 항균 수처리기
US7702430B2 (en) * 2004-11-19 2010-04-20 The Board Of Regents Of The University Of Texas System Method for designing a potential inhibitor of glutathione-aldehyde conjugate binding to aldose reductase
DE102004055998A1 (de) * 2004-11-19 2006-05-24 Rheinische Friedrich-Wilhelms-Universität Bonn Niedermolekulare Inhibitoren von Guaninnucleotid-Austauschfaktoren der Cytohesin-Familie
JP4446922B2 (ja) 2005-04-21 2010-04-07 富士通メディアデバイス株式会社 フィルタおよび分波器
EA019983B1 (ru) 2005-10-07 2014-07-30 Экселиксис, Инк. Ингибиторы mek и способы их применения
JP4493588B2 (ja) 2005-11-30 2010-06-30 京セラミタ株式会社 画像形成装置
WO2007139573A1 (en) * 2006-05-31 2007-12-06 The Trustees Of Columbia University In The City Of New York Ribosome and rna display of biologically active small molecules
US20090233972A1 (en) * 2008-03-12 2009-09-17 Yat Sun Or Substituted heterocycles as anti-infectives
JP2009233972A (ja) 2008-03-26 2009-10-15 Fujifilm Corp 液体吐出装置
KR100935543B1 (ko) 2008-04-02 2010-01-07 (주)예기산업 자연순환방식의 프리히팅장치 및 이를 이용한프리히팅시스템
WO2009154562A1 (en) * 2008-06-20 2009-12-23 Astrazeneca Ab Pharmaceutical composition comprising a 4-hydroxy-2-oxo-2, 3- dihydro-1, 3-benzothiazol-7-yl compound for modulation of beta2-adrenoreceptor activity
JP5030934B2 (ja) 2008-12-18 2012-09-19 株式会社ケーヒン エンジンの吸気制御装置における制御ケースの呼吸構造
JP5385922B2 (ja) 2009-01-29 2014-01-08 平田機工株式会社 ワーク保持移載装置
MX2012002993A (es) * 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
KR20110092501A (ko) 2010-02-09 2011-08-18 주식회사 캐러스 하이브리드 항균 펩타이드 및 이의 용도
KR101395146B1 (ko) * 2011-02-09 2014-05-16 부산대학교 산학협력단 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도
WO2013168021A1 (en) * 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
CA2909510C (en) 2013-03-15 2024-04-02 Cancer Research Technology, Llc Methods and compositions for gamma-glutamyl cycle modulation

Also Published As

Publication number Publication date
US9630936B2 (en) 2017-04-25
AU2014233168B2 (en) 2018-11-22
US20140275187A1 (en) 2014-09-18
DK2968346T3 (da) 2024-05-06
WO2014145314A2 (en) 2014-09-18
US10323009B2 (en) 2019-06-18
CA2909510A1 (en) 2014-09-18
US20190359580A1 (en) 2019-11-28
EP2968346B1 (en) 2024-02-07
JP2019065031A (ja) 2019-04-25
EP2968346A2 (en) 2016-01-20
CN105246483A (zh) 2016-01-13
AU2014233168A1 (en) 2015-11-05
AU2019201264B2 (en) 2020-07-16
WO2014145314A3 (en) 2014-11-13
KR20160003652A (ko) 2016-01-11
JP2016515531A (ja) 2016-05-30
IL283717A (en) 2021-07-29
CA2909510C (en) 2024-04-02
EA030611B1 (ru) 2018-08-31
EP2968346A4 (en) 2017-02-08
US11186555B2 (en) 2021-11-30
KR20210144942A (ko) 2021-11-30
JP6739509B2 (ja) 2020-08-12
US20170226070A1 (en) 2017-08-10
IL283717B (en) 2022-09-01
US20220324820A1 (en) 2022-10-13
IL241620B (en) 2021-06-30
JP6458000B2 (ja) 2019-01-23
CA3232320A1 (en) 2014-09-18
FI2968346T3 (fi) 2024-05-06
AU2019201264A1 (en) 2019-03-14

Similar Documents

Publication Publication Date Title
EA201591420A1 (ru) Гетероарильные соединения и их применение
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201591764A1 (ru) Варианты тканевого ингибитора металлопротеиназ третьего типа (timp-3), композиции и способы
EA201591531A1 (ru) Ингибиторы аргининметилтрансферазы и их применения
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201790661A3 (ru) Ингибиторы вируса гепатита c
EA201591961A1 (ru) Ингибиторы акк и их применение
EA201591959A1 (ru) Ингибиторы акк и их применение
EA201591960A1 (ru) Ингибиторы акк и их применение
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201591137A1 (ru) Ингибиторы mk2 и их применения
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
UA115773C2 (uk) Пірольні сполуки, спосіб їх одержання та фармацевтична композиція, що їх містить (варіанти)
EA201790785A1 (ru) Производные тетрагидроизохинолина
EA201591962A1 (ru) Ингибиторы акк и их применение
EA201500931A1 (ru) Производные пиридин-4-ила
EA201591931A1 (ru) Композиции оксабициклогептанов и оксабициклогептенов
EA201591752A1 (ru) Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы
CL2015002897A1 (es) Inhibidores de bace1
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана